Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedDF
Duquesne Family Office
Activity from announced rounds
Activity in this selectionBiotech
Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.
Recorded funding activity
Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $542M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRatio Therapeutics
Developing best-in-class radiopharmaceuticals for cancer treatment
$70MSeries C
Role not disclosedSonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedCellares
Develops automated cell therapy manufacturing platforms
$257MSeries D
Role not disclosed